Read by QxMD icon Read

Cancer death dying chemotherapy

Gregory R Bean, Jeff C Kremer, Bethany C Prudner, Aaron D Schenone, Juo-Chin Yao, Matthew B Schultze, David Y Chen, Munir R Tanas, Douglas R Adkins, John Bomalaski, Brian P Rubin, Loren S Michel, Brian A Van Tine
Sarcomas comprise a large heterogeneous group of mesenchymal cancers with limited therapeutic options. When treated with standard cytotoxic chemotherapies, many sarcomas fail to respond completely and rapidly become treatment resistant. A major problem in the investigation and treatment of sarcomas is the fact that no single gene mutation or alteration has been identified among the diverse histologic subtypes. We searched for therapeutically druggable targets that are common to a wide range of histologies and hence could provide alternatives to the conventional chemotherapy...
October 13, 2016: Cell Death & Disease
Tobin J Strom, Arash O Naghavi, Andy M Trotti, Jeffery Russell, Julie A Kish, Judith McCaffrey, Kristen J Otto, Louis B Harrison, Jimmy J Caudell
PURPOSE: Concurrent chemoradiotherapy (CRT) is the standard of care for many sites of locally advanced head and neck squamous cell carcinomas (LAHNC). However, on meta-analysis, the addition of chemotherapy did not improve survival for patients >70years. We hypothesized that elderly patients treated with CRT would have increased toxicity without similar improvements in survival. METHODS: A single-institution, IRB-approved retrospective study took place from 2005 to 2012 including 369 patients treated with CRT for LAHNC...
October 3, 2016: Journal of Geriatric Oncology
T Taki, Y Hoya, A Watanabe, T Nakayoshi, T Okamoto, H Sekine, N Mitsumori, K Yanaga
Introduction Radiotherapy is not commonly used for the treatment of gastric cancer in Japan, where surgery is the standard local treatment. We report the results of chemoradiotherapy in patients with advanced or recurrent gastric cancer which was deemed difficult to treat surgically. Methods Twenty-one patients with gastric cancer (including sixteen with advanced/recurrent gastric cancer and five with poor general condition) underwent chemo-radiotherapy, for whom the therapeutic efficacy, toxicity and survival period were analysed...
September 23, 2016: Annals of the Royal College of Surgeons of England
Minnie Bluhm, Cathleen M Connell, Raymond G De Vries, Nancy K Janz, Kathleen E Bickel, Maria J Silveira
PURPOSE: The value of chemotherapy for patients with cancer in the last weeks of life warrants examination. Late chemotherapy may not improve survival or quality of life but typically precludes hospice enrollment and may result in additional symptoms, increased use of other aggressive treatments, and worsening quality of life. Few studies have explored oncologists' rationales for administering chemotherapy near death. This study examines the self-reported factors that influence oncologists' decisions about late chemotherapy...
September 20, 2016: Journal of Oncology Practice
Yen-Ting Lin, Jacques Médioni, Grégory Amouyal, Carole Déan, Marc Sapoval, Olivier Pellerin
PURPOSE: Patients with breast cancer liver metastasis have a poor prognosis. Local therapy for liver metastasis increases survival. The purpose of this pilot prospective study was to evaluate the efficacy and safety of doxorubicin drug-eluting beads chemoembolization for liver-dominant breast cancer metastasis (LdBM) refractory to chemotherapy. MATERIALS AND METHODS: All patients with LdBM refractory to of two or more lines of systemic chemotherapy were screened...
September 19, 2016: Cardiovascular and Interventional Radiology
Jessica R Bauman, Zofia Piotrowska, Alona Muzikansky, Emily Gallagher, Emily Scribner, Brandon Temel, Lecia V Sequist, Rebecca S Heist, Jennifer S Temel
BACKGROUND/OBJECTIVE: Patients with metastatic nonsmall cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations benefit from improved survival and quality of life with EGFR-directed therapy. We sought to explore if these improvements in cancer care impacted the delivery of end-of-life (EOL) care in this population. DESIGN: We retrospectively reviewed medical records of patients cared for at our institution with the diagnosis of metastatic EGFR-mutant NSCLC who died by January 2015...
September 14, 2016: Journal of Palliative Medicine
Hari Nathan, Huiying Yin, Sandra L Wong
BACKGROUND: Recent attention has focused on the ability to rescue patients from postoperative complications and prevent short-term mortality. However, it is unknown whether patients rescued from complications after complex cancer resections have long-term survival outcomes similar to those of patients without complications. METHODS: From 2005 to 2009 Surveillance, Epidemiology, and End Results (SEER)-Medicare data, the study identified elderly patients who underwent resection for cancers of the esophagus, lung, or pancreas...
September 12, 2016: Annals of Surgical Oncology
Emilyn Banfield, Austin L Brown, Erin C Peckham, Surya P Rednam, Jeffrey Murray, M Fatih Okcu, Laura E Mitchell, Murali M Chintagumpala, Ching C Lau, Michael E Scheurer, Philip J Lupo
AIM: Medulloblastoma is the most frequent malignant pediatric brain tumor. While survival rates have improved due to multimodal treatment including cisplatin-based chemotherapy, there are few prognostic factors for adverse treatment outcomes. Notably, genes involved in the nucleotide excision repair pathway, including ERCC2, have been implicated in cisplatin sensitivity in other cancers. Therefore, this study evaluated the role of ERCC2 DNA methylation profiles on pediatric medulloblastoma survival...
October 2016: Cancer Epidemiology
Cristina Migali, Monica Milano, Dario Trapani, Carmen Criscitiello, Angela Esposito, Marzia Locatelli, Ida Minchella, Giuseppe Curigliano
Is breast cancer (BC) immunogenic? Many data suggest that it is. Many observations demonstrated the prognostic role of tumor-infiltrating lymphocytes (TILs) in triple negative (TN) and human epidermal growth factor receptor 2 (HER-2)-positive BC. TNBCs are poorly differentiated tumors with high genetic instability and very high heterogeneity. This heterogeneity enhances the 'danger signals' and select clone variants that could be more antigenic or, in other words, that could more strongly stimulate a host immune antitumor response...
September 2016: Therapeutic Advances in Medical Oncology
Scott Dryden-Peterson, Memory Bvochora-Nsingo, Gita Suneja, Jason A Efstathiou, Surbhi Grover, Sebathu Chiyapo, Doreen Ramogola-Masire, Malebogo Kebabonye-Pusoentsi, Rebecca Clayman, Abigail C Mapes, Neo Tapela, Aida Asmelash, Heluf Medhin, Akila N Viswanathan, Anthony H Russell, Lilie L Lin, Mukendi K A Kayembe, Mompati Mmalane, Thomas C Randall, Bruce Chabner, Shahin Lockman
PURPOSE: Cervical cancer is the leading cause of cancer death among the 20 million women with HIV worldwide. We sought to determine whether HIV infection affected survival in women with invasive cervical cancer. PATIENTS AND METHODS: We enrolled sequential patients with cervical cancer in Botswana from 2010 to 2015. Standard treatment included external beam radiation and brachytherapy with concurrent cisplatin chemotherapy. The effect of HIV on survival was estimated by using an inverse probability weighted marginal Cox model...
August 29, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Neyssa M Marina, Sigbjørn Smeland, Stefan S Bielack, Mark Bernstein, Gordana Jovic, Mark D Krailo, Jane M Hook, Carola Arndt, Henk van den Berg, Bernadette Brennan, Bénédicte Brichard, Ken L B Brown, Trude Butterfass-Bahloul, Gabriele Calaminus, Heike E Daldrup-Link, Mikael Eriksson, Mark C Gebhardt, Hans Gelderblom, Joachim Gerss, Robert Goldsby, Allen Goorin, Richard Gorlick, Holcombe E Grier, Juliet P Hale, Kirsten Sundby Hall, Jendrik Hardes, Douglas S Hawkins, Knut Helmke, Pancras C W Hogendoorn, Michael S Isakoff, Katherine A Janeway, Heribert Jürgens, Leo Kager, Thomas Kühne, Ching C Lau, Patrick J Leavey, Stephen L Lessnick, Leo Mascarenhas, Paul A Meyers, Hubert Mottl, Michaela Nathrath, Zsuzsanna Papai, R Lor Randall, Peter Reichardt, Marleen Renard, Akmal Ahmed Safwat, Cindy L Schwartz, Michael C G Stevens, Sandra J Strauss, Lisa Teot, Mathias Werner, Matthew R Sydes, Jeremy S Whelan
BACKGROUND: We designed the EURAMOS-1 trial to investigate whether intensified postoperative chemotherapy for patients whose tumour showed a poor response to preoperative chemotherapy (≥10% viable tumour) improved event-free survival in patients with high-grade osteosarcoma. METHODS: EURAMOS-1 was an open-label, international, phase 3 randomised, controlled trial. Consenting patients with newly diagnosed, resectable, high-grade osteosarcoma aged 40 years or younger were eligible for randomisation...
October 2016: Lancet Oncology
R P Jones, H Z Malik, S W Fenwick, M Terlizzo, E O'Grady, S Stremitzer, T Gruenberger, M Rees, G Plant, J Figueras, M Albiol, R Adam, S Awad, G J Poston
PURPOSE: Perioperative chemotherapy confers a 3-year progression free survival advantage following resection of colorectal liver metastases (CRLM), but is associated with significant toxicity. Chemoembolisation using drug eluting PVA microspheres loaded with irinotecan (DEBIRI) allows sustained delivery of drug directly to tumour, maximising response whilst minimising systemic exposure. This phase II single arm study examined the safety and feasibility of DEBIRI before resection of CRLM...
August 10, 2016: European Journal of Surgical Oncology
Bruno Mendonça Protásio, Adriana Matutino, Liana Valente Lage, Iuri Santana, Ricardo Ramos, Jorge Sabbaga, Fernanda Capareli, Daniel Saragiotto, Rachel Riechelmann, Paulo M Hoff
BACKGROUND: The efficacy and safety of the combination of a fluoropyrimidine with oxaliplatin for patients with stage III colorectal cancer (CRC) have been evaluated in selected patients who took part in clinical trials. We evaluated the outcomes of FLOX (bolus fluorouracil [5-FU] combined with oxaliplatin) in patients with resected stage III CRC treated in the community in a large cancer center. PATIENTS AND METHODS: We performed a retrospective unicenter cohort study of all consecutive stage III CRC patients who received adjuvant chemotherapy with an mFLOX (modified FLOX) regimen...
July 19, 2016: Clinical Colorectal Cancer
Rujiao Liu, Jun Cao, Xiang Gao, Jian Zhang, Leiping Wang, Biyun Wang, Lin Guo, Xichun Hu, Zhonghua Wang
High level of serum lactate dehydrogenase (LDH) is a well-known poor prognostic factor in patients with malignancies. However, there was no data on overall survival (OS) in cancer patients with serum LDH level > 1000 IU/L, and the prognostic value of the changes in LDH over time for OS had not been reported. Clinical data of 311 cancer patients with metastatic disease with serum LDH >1000 IU/L (four times upper limit of normal) admitted consecutively to a single center were reviewed in this retrospective study...
August 10, 2016: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
Heng Yang, Yuting Ma, Guo Chen, Heng Zhou, Takahiro Yamazaki, Christophe Klein, Federico Pietrocola, Erika Vacchelli, Sylvie Souquere, Allan Sauvat, Laurence Zitvogel, Oliver Kepp, Guido Kroemer
Chemotherapy can reinstate anticancer immunosurveillance through inducing tumor immunogenic cell death (ICD). Here, we show that anthracyclines and oxaliplatin can trigger necroptosis in murine cancer cell lines expressing receptor-interacting serine-threonine kinase 3 (RIP3) and mixed lineage kinase domain-like (MLKL). Necroptotic cells featured biochemical hallmarks of ICD and stimulated anticancer immune responses in vivo. Chemotherapy normally killed Rip3 (-/-) and Mlkl (-/-) tumor cells and normally induced caspase-3 activation in such cells, yet was unable to reduce their growth in vivo...
June 2016: Oncoimmunology
Fred R Hirsch, Ramaswamy Govindan, Zanete Zvirbule, Fadi Braiteh, Achim Rittmeyer, Cristóbal Belda-Iniesta, Dolores Isla, Thomas Cosgriff, Michelle Boyer, Masamichi Ueda, See Phan, David R Gandara
INTRODUCTION: The treatment options for squamous cell non-small-cell lung cancer (NSCLC) are limited. We assessed the efficacy and safety of onartuzumab plus platinum-doublet chemotherapy in previously untreated advanced squamous cell NSCLC. PATIENTS AND METHODS: The patients were randomized to receive onartuzumab plus paclitaxel plus carboplatin/cisplatin (n = 55) or placebo plus paclitaxel plus carboplatin/cisplatin (n = 54). Randomization was stratified by MET diagnostic status: MET immunohistochemistry (IHC)-positive (MET IHC 3+/2+) or MET IHC-negative (MET IHC 1+/0)...
June 4, 2016: Clinical Lung Cancer
Lucas Morin, Yvan Beaussant, Régis Aubry, Johan Fastbom, Kristina Johnell
OBJECTIVES: To compare the aggressiveness of end-of-life care in hospitalized individuals with cancer with and without dementia in France. DESIGN: Nationwide register-based matched-cohort study. SETTING: Hospital facilities in France. PARTICIPANTS: All individuals with cancer aged 65 and older with a diagnosis of dementia who died between January 1, 2010 and December 31, 2013, matched one-to-one with individuals with cancer without dementia (n = 26,782 matched pairs)...
September 2016: Journal of the American Geriatrics Society
Vijay Mohan, Rajesh Agarwal, Rana P Singh
Lung cancer is the most frequently diagnosed malignancy that contributes to high proportion of deaths globally among patients who die due to cancer. Chemotherapy remains the common mode of treatment for lung cancer patients though with limited success. We assessed the biological effects and associated molecular changes of evodiamine, a plant alkaloid, on human lung cancer A549 and H1299 cells along with other epithelial cancer and normal lung SAEC cells. Our data showed that 20-40 μM evodiamine treatment for 24-48 h strongly (up to 73%, P < 0...
September 2, 2016: Biochemical and Biophysical Research Communications
Alessio Terenzi, Christine Pirker, Bernhard K Keppler, Walter Berger
Conventional chemotherapeutics, but also innovative precision anticancer compounds, are commonly perceived to target primarily the cancer cell compartment. However, recently it was discovered that some of these compounds can also exert immunomodulatory activities which might be exploited to synergistically enhance their anticancer effects. One specific phenomenon of the interplay between chemotherapy and the anticancer immune response is the so-called "immunogenic cell death" (ICD). ICD was discovered based on a vaccination effect exerted by cancer cells dying from pretreatment with certain chemotherapeutics, termed ICD inducers, in syngeneic transplantation mouse models...
June 16, 2016: Journal of Inorganic Biochemistry
Hany Abdel Rahman Sayed, Mohamed Sedky, Asmaa Hamoda, Naglaa El Kinaaie, Madeha El Wakeel, Dina Hesham
Introduction Lymphoblastic lymphoma (LBL) and acute lymphoblastic leukemia (ALL) are neoplasms of immature B or T-cell precursors. They are considered as a unique biological entity in the 2008 World Health Organization Classification of Hematologic Neoplasm. Both entities are arbitrarily separated by a cut-off point of 20-25% of blast cells in the bone marrow. Treatment of LBL has evolved over time from conventional high-grade NHL schedules to ALL-derived protocols. The aim of this work is to report the clinical characteristics, overall survival (OS), event free survival (EFS), and common chemotherapy toxicities of lymphoblastic lymphoma (LBL) patients during a 5...
September 2016: Journal of the Egyptian National Cancer Institute
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"